HRTS Price Forecast & ETF Analysis. Dividend · Expense Ratio · Holdings · NAV · RSI · MACD | US Stocks Today
Oct 16 at 4:00 PM ET (Korea 10/17 05:00)
Full metrics table
| Category | Global or ExUS Equities - Industry Sector | Expense | 0.75% | Return% 1Y | 17.39% | Total Holdings | 46 | Perf Week | 1.89% | Volume | 2,359 |
| Asset Type | Equities (Stocks) | AUM | $55M | Return% 3Y | - | NAV | $37.23 | Perf Month | 1.17% | Avg Volume | 0.00M |
| ETF Type | Global Equities | Dividend TTM | $0.47 (1.28%) | Return% 5Y | - | 52W High | -5.05% | Perf Quarter | 2.78% | Rel Volume | 0.62 |
| Active/Passive | Active | Div Gr. 3/5Y | - | Return% 10Y | - | 52W Low | 15.5% | Perf Half Y | 6.54% | Prev Close | $37.23 |
| IPO | 2023/11/21 | Flows% 1M | -0.65% | Return% SI | 13.35% | RSI (14) | 55.28 | Perf YTD | 4.57% | Price | $36.90 |
| Beta | 0.65 | Flows% 3M | -0.65% | Flows% YTD | -4.35% | Flows% 1Y | -5.15% | Perf Year | 14.76% | Volatility(W/M) | 0.65% 0.74% |
| SMA20 | 1.85% | SMA50 | -0.1% | SMA200 | 4.1% | ATR | 0.46 | ||||
Tema Cardiovascular and Metabolic ETF seeks to provide long-term growth of capital. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund advisor generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.
The top 10 make up 49% of the fund
LLY Eli Lilly & Co 11.52% 2 
UNH UnitedHealth Group Inc 5.24% 3 
NVO Novo Nordisk A/S 5.24% 4 
RHHBY Roche Holding AG 4.50% 5 
MRK Merck & Co Inc 4.27% 6 
AZN AstraZeneca PLC 4.00% 7 
TMO Thermo Fisher Scientific Inc 3.97% 8 
JNJ Johnson & Johnson 3.59% 9 
GILD Gilead Sciences Inc 3.43% 10 
NVS Novartis AG 3.38% Largest sectors first.
Over the past 1 year, roughly in the middle
5% below its 1-year high.
Traded less than usual. That is 62% of its average volume.
Long-term returns are roughly flat
Tap to view numbers
The price swings a lot
At its worst (July 2024) it fell 26% and took 231 days to recover.
Tap to view numbers
The dividend is on the small side
Pays 1.28% annually in dividends.
Tap to view numbers
A lot of money is flowing out
Over the past year, money equal to 5.2% of assets left.
Tap to view numbers
CURE Direxion Daily Healthcare Bull 3X ETF 186M 
RXL ProShares Ultra Health Care 2X Shares 103M 
XLVI State Street Health Care Select Sector SPDR Premium Income ETF 31M 
RXD-1× ProShares UltraShort Health Care -2x Shares 3M 
TBXU Direxion Daily Biotech Top 5 Bull 2X ETF 3M 
DRAM Roundhill Memory ETF 0.65% 
SECT Main Sector Rotation ETF 0.69% 
AVRE Avantis Real E state ETF 0.17% 
VOLT Tema Electrification ETF 0.75% 
CANC Tema Oncology ETF 0.75% 
HAUZ Xtrackers International Real Estate ETF 0.1% 
VNQI Vanguard Global ex-U.S. Real Estate ETF 0.12% 
PBPH Portfolio Building Block World Pharma and Biotech Index ETF 0.13% 
FAQ
How many holdings does HRTS have?
HRTS holds a total of 46 securities, with an AUM of approximately $55M.
Does HRTS pay dividends (distributions)?
HRTS's distribution yield is approximately 1.28%.
What is the 52-week high and low for HRTS?
HRTS has recorded a 52-week high of $38.87 and a low of $31.95.
